


CAS SCIFINDER
DISCOVERY PLATFORM™

ACCELERATING LEAD GENERATION WITH SCIENTIFIC INFORMATION



Solution success story

The challenge: Choosing the right lead candidates

Medicinal chemists face many hurdles when identifying and validating compounds for drug development. Beyond understanding complex biological pathways and assessing lead candidates for biological relevance, they operate in an increasingly crowded field. This often includes competitors big and small, who may have identified and protected the same or similar compounds.

For Dr. Joel Van Gelder - a medicinal chemist with more than 25 years of experience - identifying the most promising lead candidates is critical to deciding budget allocation; the biotechnology start-ups he has been advising could not afford to lose time on unviable development processes. A few years ago, as the lead scientist in a small biotech company with limited resources, he faced a significant challenge to decide between two small molecule candidates targeting a specific kinase.

With the exponential increase in publications, patents, and scientific data worldwide, researchers are tasked with finding the most relevant information quickly and accurately. In practice, this is difficult to implement due to the fragmentation of scientific information and limited interconnection among scientific databases. Dr. Van Gelder needed a quick and cost-effective way to assess all existing information of his two lead candidates and decide which one to progress for drug development.

CAS

A division of the
American Chemical Society



The solution: Identifying promising drug candidates confidently

CAS SciFinder® provides access to the CAS Content Collection™, the world's largest curated scientific database, which can help medicinal chemists find and validate their lead compounds more effectively.

Using the unique chemical structure searching and integrated patent information in CAS SciFinder, the lead candidates were found to be new chemical entities (NCEs). By using an Alert for the substructure search in the solution, which gives access to the latest research, Dr. Van Gelder noticed that one of his lead candidates popped up in a newly published patent application and was tested for the same biological target and medical indication by a big pharmaceutical company. Armed with this knowledge, he diverted resources away from this compound and worked on the alternative lead.

By taking advantage of the unique combination of powerful features and comprehensive, up-to-date information, Dr. Van Gelder confidently identified the most appropriate lead candidate. This prevented potential delays and constraints on budget resources.



"Using CAS SciFinder led to hundreds of thousands in cost savings by avoiding resources spent on the wrong lead; this can be critical for the survival of biotechnology start-ups."

Dr. Joel Van Gelder
Chief Innovation Officer
Interna Therapeutics

Find out how the CAS SciFinder Discovery Platform can help you accelerate scientific discovery and drive innovation. Build your R&D process on the best information and tools that empower your teams to do their best work.

Learn more at cas.org